120 related articles for article (PubMed ID: 36516883)
1. BRD4 inhibitor suppresses melanoma metastasis via the SPINK6/EGFR-EphA2 pathway.
Hu R; Li Y; Guo Y; Li X; Du S; Liao M; Hou H; Sun H; Zhao S; Su J; Chen X; Yin M
Pharmacol Res; 2023 Jan; 187():106609. PubMed ID: 36516883
[TBL] [Abstract][Full Text] [Related]
2. SPINK6 Promotes Metastasis of Nasopharyngeal Carcinoma via Binding and Activation of Epithelial Growth Factor Receptor.
Zheng LS; Yang JP; Cao Y; Peng LX; Sun R; Xie P; Wang MY; Meng DF; Luo DH; Zou X; Chen MY; Mai HQ; Guo L; Guo X; Shao JY; Huang BJ; Zhang W; Qian CN
Cancer Res; 2017 Jan; 77(2):579-589. PubMed ID: 27671677
[TBL] [Abstract][Full Text] [Related]
3. BRD4 sustains melanoma proliferation and represents a new target for epigenetic therapy.
Segura MF; Fontanals-Cirera B; Gaziel-Sovran A; Guijarro MV; Hanniford D; Zhang G; González-Gomez P; Morante M; Jubierre L; Zhang W; Darvishian F; Ohlmeyer M; Osman I; Zhou MM; Hernando E
Cancer Res; 2013 Oct; 73(20):6264-76. PubMed ID: 23950209
[TBL] [Abstract][Full Text] [Related]
4. BET inhibitor suppresses melanoma progression
Deng G; Zeng F; Su J; Zhao S; Hu R; Zhu W; Hu S; Chen X; Yin M
Theranostics; 2020; 10(25):11428-11443. PubMed ID: 33052224
[No Abstract] [Full Text] [Related]
5. Harnessing BET Inhibitor Sensitivity Reveals AMIGO2 as a Melanoma Survival Gene.
Fontanals-Cirera B; Hasson D; Vardabasso C; Di Micco R; Agrawal P; Chowdhury A; Gantz M; de Pablos-Aragoneses A; Morgenstern A; Wu P; Filipescu D; Valle-Garcia D; Darvishian F; Roe JS; Davies MA; Vakoc CR; Hernando E; Bernstein E
Mol Cell; 2017 Nov; 68(4):731-744.e9. PubMed ID: 29149598
[TBL] [Abstract][Full Text] [Related]
6. BET inhibitors synergize with sunitinib in melanoma through GDF15 suppression.
Zeng F; Li Y; Meng Y; Sun H; He Y; Yin M; Chen X; Deng G
Exp Mol Med; 2023 Feb; 55(2):364-376. PubMed ID: 36720918
[TBL] [Abstract][Full Text] [Related]
7. EGFR-mediated signaling pathway influences the sensitivity of oral squamous cell carcinoma to JQ1.
Liu X; Li Q; Huang P; Tong D; Wu H; Zhang F
J Cell Biochem; 2018 Oct; 119(10):8368-8377. PubMed ID: 30687956
[TBL] [Abstract][Full Text] [Related]
8. A 7-methoxybicoumarin derivative selectively inhibits BRD4 BD2 for anti-melanoma therapy.
Yang GJ; Wang W; Lei PM; Leung CH; Ma DL
Int J Biol Macromol; 2020 Dec; 164():3204-3220. PubMed ID: 32860796
[TBL] [Abstract][Full Text] [Related]
9. Serine protease inhibitor kazal-type 6 inhibits tumorigenesis of human hepatocellular carcinoma cells via its extracellular action.
Ge K; Huang J; Wang W; Gu M; Dai X; Xu Y; Wu H; Li G; Lu H; Zhong J; Huang Q
Oncotarget; 2017 Jan; 8(4):5965-5975. PubMed ID: 27999203
[TBL] [Abstract][Full Text] [Related]
10. BRD4 promotes p63 and GRHL3 expression downstream of FOXO in mammary epithelial cells.
Nagarajan S; Bedi U; Budida A; Hamdan FH; Mishra VK; Najafova Z; Xie W; Alawi M; Indenbirken D; Knapp S; Chiang CM; Grundhoff A; Kari V; Scheel CH; Wegwitz F; Johnsen SA
Nucleic Acids Res; 2017 Apr; 45(6):3130-3145. PubMed ID: 27980063
[TBL] [Abstract][Full Text] [Related]
11. Spatially constrained tandem bromodomain inhibition bolsters sustained repression of BRD4 transcriptional activity for TNBC cell growth.
Ren C; Zhang G; Han F; Fu S; Cao Y; Zhang F; Zhang Q; Meslamani J; Xu Y; Ji D; Cao L; Zhou Q; Cheung KL; Sharma R; Babault N; Yi Z; Zhang W; Walsh MJ; Zeng L; Zhou MM
Proc Natl Acad Sci U S A; 2018 Jul; 115(31):7949-7954. PubMed ID: 30012592
[TBL] [Abstract][Full Text] [Related]
12. DUB3 Promotes BET Inhibitor Resistance and Cancer Progression by Deubiquitinating BRD4.
Jin X; Yan Y; Wang D; Ding D; Ma T; Ye Z; Jimenez R; Wang L; Wu H; Huang H
Mol Cell; 2018 Aug; 71(4):592-605.e4. PubMed ID: 30057199
[TBL] [Abstract][Full Text] [Related]
13. Super-enhancers define a proliferative PGC-1α-expressing melanoma subgroup sensitive to BET inhibition.
Gelato KA; Schöckel L; Klingbeil O; Rückert T; Lesche R; Toedling J; Kalfon E; Héroult M; Lejeune P; Mönning U; Fernández-Montalván AE; Bäurle S; Siegel S; Haendler B
Oncogene; 2018 Jan; 37(4):512-521. PubMed ID: 28991225
[TBL] [Abstract][Full Text] [Related]
14. Brd4 inhibition attenuates unilateral ureteral obstruction-induced fibrosis by blocking TGF-β-mediated Nox4 expression.
Zhou B; Mu J; Gong Y; Lu C; Zhao Y; He T; Qin Z
Redox Biol; 2017 Apr; 11():390-402. PubMed ID: 28063381
[TBL] [Abstract][Full Text] [Related]
15. Gingipains of Porphyromonas gingivalis Affect the Stability and Function of Serine Protease Inhibitor of Kazal-type 6 (SPINK6), a Tissue Inhibitor of Human Kallikreins.
Plaza K; Kalinska M; Bochenska O; Meyer-Hoffert U; Wu Z; Fischer J; Falkowski K; Sasiadek L; Bielecka E; Potempa B; Kozik A; Potempa J; Kantyka T
J Biol Chem; 2016 Sep; 291(36):18753-64. PubMed ID: 27354280
[TBL] [Abstract][Full Text] [Related]
16. BRD4 isoforms have distinct roles in tumour progression and metastasis in rhabdomyosarcoma.
Das D; Leung JY; Balamurugan S; Tergaonkar V; Loh AHP; Chiang CM; Taneja R
EMBO Rep; 2024 Feb; 25(2):832-852. PubMed ID: 38191874
[TBL] [Abstract][Full Text] [Related]
17. Targeting BRD4 proteins suppresses the growth of NSCLC through downregulation of eIF4E expression.
Gao Z; Yuan T; Zhou X; Ni P; Sun G; Li P; Cheng Z; Wang X
Cancer Biol Ther; 2018 May; 19(5):407-415. PubMed ID: 29333921
[TBL] [Abstract][Full Text] [Related]
18. Discovery of a series of dihydroquinoxalin-2(1H)-ones as selective BET inhibitors from a dual PLK1-BRD4 inhibitor.
Hu J; Wang Y; Li Y; Xu L; Cao D; Song S; Damaneh MS; Wang X; Meng T; Chen YL; Shen J; Miao Z; Xiong B
Eur J Med Chem; 2017 Sep; 137():176-195. PubMed ID: 28586718
[TBL] [Abstract][Full Text] [Related]
19. Targeting non-canonical activation of GLI1 by the SOX2-BRD4 transcriptional complex improves the efficacy of HEDGEHOG pathway inhibition in melanoma.
Pietrobono S; Gaudio E; Gagliardi S; Zitani M; Carrassa L; Migliorini F; Petricci E; Manetti F; Makukhin N; Bond AG; Paradise BD; Ciulli A; Fernandez-Zapico ME; Bertoni F; Stecca B
Oncogene; 2021 Jun; 40(22):3799-3814. PubMed ID: 33958721
[TBL] [Abstract][Full Text] [Related]
20. BRD4 bimodal binding at promoters and drug-induced displacement at Pol II pause sites associates with I-BET sensitivity.
Khoueiry P; Ward Gahlawat A; Petretich M; Michon AM; Simola D; Lam E; Furlong EE; Benes V; Dawson MA; Prinjha RK; Drewes G; Grandi P
Epigenetics Chromatin; 2019 Jul; 12(1):39. PubMed ID: 31266503
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
